novo nordisk weight loss

Novo Nordisk's next-gen obesity drug Cagrisema

CNBC on MSN · 31m

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Hosted on MSN · 4h

Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

Reuters · 7h

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

Novo Nordisk, NVO

Insider Monkey on MSN · 4h

Why Novo Nordisk (NVO) Is Climbing Today

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported higher-than-expected net income for the fourth quarter.

The Wall Street Journal on MSN · 6h

Novo Nordisk Outlook Provides Some Welcome Relief

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing capacity constraints and fears over the U.S. demand outlook for Wegovy.

Business Insider · 7h

Novo Nordisk (NVO) Receives a Buy from TD Cowen

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

The Motley Fool3d

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering ...

Yahoo Finance12d

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...

Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk beats on Wegovy sales, expects slower 2025 growth

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

1don MSN

Healthy Returns: Why people quit weight loss, diabetes drugs within one year

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results